Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study.
Saved in:
| Title: | Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study. |
|---|---|
| Authors: | Thein KZ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. theink@ohsu.edu.; Division of Hematology and Medical Oncology, Oregon Health and Science University/ Knight Cancer Institute, Portland, OR, USA. theink@ohsu.edu., Karp DD; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Tsimberidou A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gong J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sulovic S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Shah J; Karyopharm Therapeutics, Newton, MA, USA., Milton DR; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Janku F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., McQuinn L; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Stephen BA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Colen R; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Carter BW; Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yap TA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Piha-Paul SA; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Meric-Bernstam F; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. |
| Source: | Investigational new drugs [Invest New Drugs] 2022 Apr; Vol. 40 (2), pp. 463. |
| Publication Type: | Published Erratum |
| Journal Info: | Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE; PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 34731355 AccessLevel: 2 PubTypeId: unknown PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Thein+KZ%22">Thein KZ</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. theink@ohsu.edu.; Division of Hematology and Medical Oncology, Oregon Health and Science University/ Knight Cancer Institute, Portland, OR, USA. theink@ohsu.edu.<br /><searchLink fieldCode="AU" term="%22Karp+DD%22">Karp DD</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Tsimberidou+A%22">Tsimberidou A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Gong+J%22">Gong J</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Sulovic+S%22">Sulovic S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Shah+J%22">Shah J</searchLink>; Karyopharm Therapeutics, Newton, MA, USA.<br /><searchLink fieldCode="AU" term="%22Milton+DR%22">Milton DR</searchLink>; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Hong+DS%22">Hong DS</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Janku+F%22">Janku F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22McQuinn+L%22">McQuinn L</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Stephen+BA%22">Stephen BA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Colen+R%22">Colen R</searchLink>; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Carter+BW%22">Carter BW</searchLink>; Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Yap+TA%22">Yap TA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Piha-Paul+SA%22">Piha-Paul SA</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Fu+S%22">Fu S</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Meric-Bernstam+F%22">Meric-Bernstam F</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.<br /><searchLink fieldCode="AU" term="%22Naing+A%22">Naing A</searchLink>; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.; Department of Thoracic Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2022 Apr; Vol. 40 (2), pp. 463. – Name: TypePub Label: Publication Type Group: TypPub Data: Published Erratum – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE; PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34731355 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s10637-021-01194-3 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 463 Titles: – TitleFull: Correction to: Selinexor in combination with carboplatin and paclitaxel in patients with advanced solid tumors: results of a single‑center, multi‑arm phase Ib study. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Thein KZ – PersonEntity: Name: NameFull: Karp DD – PersonEntity: Name: NameFull: Tsimberidou A – PersonEntity: Name: NameFull: Gong J – PersonEntity: Name: NameFull: Sulovic S – PersonEntity: Name: NameFull: Shah J – PersonEntity: Name: NameFull: Milton DR – PersonEntity: Name: NameFull: Hong DS – PersonEntity: Name: NameFull: Janku F – PersonEntity: Name: NameFull: McQuinn L – PersonEntity: Name: NameFull: Stephen BA – PersonEntity: Name: NameFull: Colen R – PersonEntity: Name: NameFull: Carter BW – PersonEntity: Name: NameFull: Yap TA – PersonEntity: Name: NameFull: Piha-Paul SA – PersonEntity: Name: NameFull: Fu S – PersonEntity: Name: NameFull: Meric-Bernstam F – PersonEntity: Name: NameFull: Naing A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 04 Text: 2022 Apr Type: published Y: 2022 Identifiers: – Type: issn-electronic Value: 1573-0646 Numbering: – Type: volume Value: 40 – Type: issue Value: 2 Titles: – TitleFull: Investigational new drugs Type: main |
| ResultId | 1 |
